Trial Profile
Expanded Access to RXDX-105 for the Treatment of Cancers With RET Alterations
Status:
Completed
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs RXDX 105 (Primary)
- Indications Cancer
- Focus Expanded access; Therapeutic Use
- Sponsors Ignyta; Roche
- 24 Apr 2019 Status changed from Suspended to completed.
- 14 Aug 2017 Status changed from recruiting to suspended.
- 17 Feb 2017 New trial record